Evidence map›Paper›PMID 36755690›Full record

ArticleBioMed research international2023

Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma.

Yushan Zhang, Liangyu He, Lixin Pan, Chao Feng, Xi Wang, Yuting Tao, Tianyu Li, Qiuyan Wang, Hanif Ullah

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yushan ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, Guangxi 530021, China.ORCID https://orcid.org/0000-0003-4548-8073
Liangyu HeCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0002-0570-7377
Lixin PanCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0002-3491-5095
Chao FengCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0002-9016-6682
Xi WangCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0003-3566-4192
Yuting TaoDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Guangxi Medical University, Nanning, Guangxi 530021, China.ORCID https://orcid.org/0000-0002-2281-0640
Tianyu LiCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0003-0833-8762
Qiuyan WangCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0001-9372-4435
Hanif UllahCenter for Genomic and Personalized Medicine, Guangxi Medical University, Nanning 530021, China.ORCID https://orcid.org/0000-0002-8034-8255
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Hepatocellular carcinoma (HCC) is a disease with great heterogeneity and a high mortality rate. It is crucial to identify reliable biomarkers for diagnosis, prognosis, and treatment to improve clinical outcomes in patients with HCC. Alpha-fetoprotein (AFP) is not only a widely used biomarker in clinical practice but also plays a complicated role in HCC, and it has recently been considered to be related to immunotherapy. MicroRNAs (miRNAs) are regarded as key regulators and promising biomarkers of HCC. We investigated the role of an AFP-related miRNA, miR-135b-5p, in HCC progression. Methods: Identification of miR-135b-5p was performed based on a cohort of 65 HCC cases and the liver hepatocellular carcinoma cohort of The Cancer Genome Atlas (Asian people only). A combination of whole-transcriptome sequencing and high-dimensional proteomic technologies was used to study the role of miR-135b-5p in HCC. Results: Upregulation of miR-135b-5p was detected in patients with HCC with high serum AFP levels (AFP > 400 ng/ml). Elevated miR-135b-5p expression was associated with adverse prognosis. We also identified the relevance between high miR-135b-5p expression and tumor-related pathological characteristics, such as Edmondson grade and vascular invasion. We revealed tyrosine kinase nonreceptor 1 as a potential target of miR-135b-5p. Additionally, the transcriptional start site of miR-135b-5p had potential binding sites for SRY-box transcription factor 9, and the stemness properties of tumor cells were more remarkable in HCC with the upregulation of miR-135b-5p. The molecular characterization of the miR-135b-5p-high group was similar to that of the HCC subclasses containing moderately and poorly differentiated tumors. Finally, gene signatures associated with improved clinical outcomes in immune checkpoint inhibitor therapy were upregulated in the miR-135b-5p-high group. Conclusion: miR-135b-5p could be a biomarker for predicting the prognosis and antiprogrammed cell death protein 1 monotherapy response in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsalpha-FetoproteinsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansProteomicsTranscriptomealpha-FetoproteinsBiomarkers, TumorMicroRNAsMIRN135 microRNA, human

Identifiers

PMID36755690
PMCPMC9902149
OpenAlexW4318484707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.